Table 2 Per cycle dosimetry, effective half-life and response one month after final cycle for all patients
Patient‡ | Per cycle | Cumulative | Follow up | ||||
|---|---|---|---|---|---|---|---|
Tumour absorbed dose (Gy) | Tumour effective half-life (h) | Kidney absorbed dose (Gy) | Kidney effective half-life (h) | Tumour absorbed dose (Gy) | Kidney absorbed dose (Gy) | Δ in tumour dimension | |
P1-1 | 21.3 | 54.0 | 2.60 | 85.5 | 21.3 | 2.6 | – |
P1-2 | 11.4 | 39.0 | 3.18 | 71.3 | 32.7 | 5.78 | – |
P1-3 | 32.9 | 26.5 | 1.47 | 43.8 | 65.6 | 7.25 | – |
P1-4 | 6.6 | 31.2 | 4.02 | 47.0 | 72.2 | 11.27 | + 4.65% |
P2-1 | 13.5 | 43.6 | 1.00 | 109.5 | 13.5 | 1 | – |
P2-2 | 11.4 | 37.8 | 1.03 | 102.0 | 24.9 | 2.03 | − 1.86% * |
P2-3 | 17.7 | 20.0 | 1.66 | 69.8 | 42.6 | 3.69 | – |
P2-4 | 0.72 | 29.8 | 1.81 | 73.4 | 43.32 | 5.5 | – |
P3-1 | 8.12 | 51.0 | 1.28 | 153.1 | 8.12 | 1.28 | – |
P3-2 | 9.67 | 37.7 | 1.19 | 93.4 | 17.79 | 2.47 | – |
P3-3 | 2.73 | 24.8 | 1.28 | 87.9 | 20.52 | 3.75 | – |
P3-4 | 10.4 | 25.9 | 1.98 | 118.4 | 30.92 | 5.73 | − 5.47% |
P4-1 | 17.7 | 40.9 | 1.53 | 39.8 | 17.7 | 1.53 | – |
P4-2 | 24.9 | 40.3 | 1.59 | 82.4 | 42.6 | 3.12 | – |
P4-3 | 7.5 | 22.9 | 2.87 | 86.7 | 50.1 | 5.99 | – |
P4-4 | 20.1 | 35.5 | 2.82 | 57.8 | 70.2 | 8.81 | + 4.26% |
P5-1 | 11.8 | 57.8 | 0.66 | 91.7 | 11.8 | 0.66 | a |
P5-2 | 11.3 | 47.6 | 0.66 | 132.9 | 23.1 | 1.32 | a |
P5-3 | 4.15 | 25.8 | 1.77 | 95.0 | 27.25 | 3.09 | a |
P5-4 | 1.92 | 35.1 | 1.79 | 26.9 | 29.17 | 4.88 | a |
P6-1 | 26.4 | 56.2 | 2.32 | 102.5 | 26.4 | 2.32 | – |
P6-2 | 28.8 | 43.8 | 3.20 | 146.1 | 55.2 | 5.52 | – |
P6-3 | 15.2 | 30.5 | 3.03 | 52.0 | 70.4 | 8.55 | – |
P6-4 | 1.00 | 32.5 | 3.03 | 100.6 | 71.4 | 11.58 | − 2.08% |
Median | 11.4 | 36.6 | 1.78 | 87.3 | 30.0 | 3.72 | |